Comparison · NCT03262662-3326faad
Extended Run-In vs Standard Run-In: Number of Participants With Continuous Abstinence at End-of-Treatment (EOT) as Assessed by Self-Report and Bio-verification
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. Extended Run-In vs Standard Run-In: Number of Participants With Continuous Abstinence at End-of-Treatment (EOT) as Assessed by Self-Report and Bio-verification. Trial comparisons, record NCT03262662-3326faad. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT03262662-3326faad
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.393 | 0.321 | 0.469 | wilson | |
| Risk in group 2 | 0.363 | 0.292 | 0.441 | wilson | |
| Risk difference, group 1 minus group 2 | 0.0296 | -0.0761 | 0.134 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 1.08 | 0.816 | 1.43 | log | |
| Odds ratio, group 1 over group 2 | 1.13 | 0.721 | 1.78 | log | |
| Number needed to treat, for one more participant with the outcome on Extended Run-In than on Standard Run-In | 33.8 | from the risk difference interval | the interval includes no difference |
Source ClinicalTrials.gov
Groups2
Neither group, or both, names a comparator, so the groups keep ClinicalTrials.gov's order.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | Extended Run-In | \*\* 4 weeks of varenicline prior to the target quit date (TQD) \*\*~\+ 11 weeks of post-TQD varenicline~Standard varenicline dosing titration in initial week of therapy (one 0.5 mg tablet orally daily x 3 days, then one 0.5 mg tablet twice daily x 4 days); then 1 mg twice daily thereafter.~Brief individual counseling at clinic visits~Varenicline: oral varenicline tablets~Brief smoking cessation counseling: \~10-minute individual counseling at each of 6 clinic visits | 64 | 163 | OG000 |
| Group 2 | Standard Run-In | \*\* 3 weeks of placebo followed by 1 week of varenicline prior to the target quit date (TQD) \*\*~\+ 11 weeks of post-TQD varenicline~Standard varenicline dosing titration in initial week of therapy (one 0.5 mg tablet orally daily x 3 days, then one 0.5 mg tablet twice daily x 4 days); then 1 mg twice daily thereafter.~Brief individual counseling at clinic visits~Varenicline: oral varenicline tablets~Brief smoking cessation counseling: \~10-minute individual counseling at each of 6 clinic visits | 57 | 157 | OG001 |
Source ClinicalTrials.gov
Outcome
- Type
- PRIMARY
- Title
- Number of Participants With Continuous Abstinence at End-of-Treatment (EOT) as Assessed by Self-Report and Bio-verification
- Description
- Number of participants with bio-verified (cotinine level of 15 ng/mL or less) self-reported continuous abstinence from smoking (not even a puff) during the final four weeks of treatment
- Time frame
- Self-report Treatment Weeks 12-15; bio-verification ~Week 16
- Population
- Intent-to-treat analysis.
Source ClinicalTrials.gov
Trial
- Title
- EVarQuit: Extended Pre-quit Varenicline to Assist in Quitting Smoking
- NCT number
- NCT03262662
- Phases
- PHASE3
- Conditions
- Tobacco Smoking
- Interventions
- Varenicline, Brief smoking cessation counseling
- Lead sponsor
- State University of New York at Buffalo
- Results first posted
- 2023-07-11
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT03262662?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT03262662-3326faad